Recombinant protein technologies are now standard and the current focus has shifted from the method of bulk production to post-production techniques that promise to enhance stability and delivery. In the effort to produce orally available therapeutics, formulation issues have become critical. (Source: BCC)

Advances in recombinant antibodies have impact on a range of therapy areas, such as oncology, CNS, infectious and inflammatory diseases. With an expert line-up of speakers, 3rd Annual Recombinant Antibodies Conference is an ideal forum for industry and academia alike. This 2-day event will explore novel applications of antibodies, recent advances in antibody engineering and the latest clinical developments.

By attending this conference you will:
• Examine future trends in global antibody development
• Hear the latest strategies for protecting antibodies and receive relevant regulatory information
• Reduce immunogenicity risk by overcoming immune reactions to improve clinical applications of antibody therapeutics
• Explore recent developments in antibody therapy against infl ammatory/ autoimmune diseases
• Improve clinical study design
• Hear case studies on developments of recombinant antibodies as cancer therapeutics